Brokerages Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Target Price at $12.50

ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Free Report) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $12.50.

ALXO has been the subject of several recent research reports. UBS Group lowered their price objective on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Monday, August 12th. Lifesci Capital lowered ALX Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 31st. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Tuesday, August 13th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th.

View Our Latest Analysis on ALXO

ALX Oncology Stock Up 2.0 %

Shares of ALX Oncology stock opened at $1.52 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.39 and a current ratio of 4.39. ALX Oncology has a 52-week low of $1.34 and a 52-week high of $17.83. The stock has a market capitalization of $80.06 million, a price-to-earnings ratio of -0.42 and a beta of 1.03. The company’s 50 day moving average price is $1.83 and its 200-day moving average price is $6.35.

ALX Oncology (NASDAQ:ALXOGet Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.01. Equities research analysts forecast that ALX Oncology will post -3.04 EPS for the current year.

Institutional Investors Weigh In On ALX Oncology

A number of large investors have recently made changes to their positions in ALXO. CANADA LIFE ASSURANCE Co purchased a new position in shares of ALX Oncology during the 1st quarter valued at about $27,000. EntryPoint Capital LLC purchased a new position in ALX Oncology in the 1st quarter worth approximately $32,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after purchasing an additional 5,200 shares in the last quarter. Rhumbline Advisers lifted its holdings in ALX Oncology by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after purchasing an additional 5,360 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in ALX Oncology by 50.7% in the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after purchasing an additional 6,080 shares in the last quarter. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Company Profile

(Get Free Report

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

Read More

Analyst Recommendations for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.